Ultime notizie per Outfront Media (NYSE:OUT) Azioni

Outfront Media

Outfront Media Inc is a real estate investment trust involved in the ownership of advertising space on its portfolio of billboards and transit displays. The Company generates revenue in the form of rental income by allowing other companies to advertise on its properties and structures under short-term contracts. Outfront Media segments its operations into the United States and International units. Although it also owns assets in Canada and Latin America, the company derives the vast majority of its revenue from billboard advertising agreements in the U.S. Roughly half of the U.S. division's revenue comes from its displays in the New York City and Los Angeles markets. Outfront Media's major customers include entities within the retail, television, healthcare, and entertainment industries.

Outfront Media Inc

OUTBACK OIL&MNRL EXPL CRP by Outback Oil & Mineral Exploration Corp.

Outback Oil & Mineral Exploration Corp

Outokumpu Oyj

Space Acquisition Corp. I

Procter &amp; Gamble Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) shares are trading lower after the company reported&nbsp;first-quarter&nbsp;sales of&nbsp;$21.74 billion&nbsp;(-1% Y/Y),&nbsp;missing the analyst <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41399117/p-g-announces-fiscal-year-2025-first-quarter-results" rel="noreferrer noopener">consensus estimate of&nbsp;$21.91 billion</a>.
Organic sales, which exclude the impacts of foreign exchange and acquisitions and divestitures, increased&nbsp;by 2%.
Organic sales growth was driven by a 1% increase in higher pricing and a 1% rise in organic volume, excluding the effects of acquisitions and divestitures.
Sales in the Beauty segment fell&nbsp;5%, and the Baby, Feminine &amp; Family Care segment declined 2%.
Meanwhile, the Grooming segment sales sales remained flat, while Fabric &amp; Home Care grew 1% and Health Care sales increased&nbsp;2%.
Gross profit remained flat&nbsp;at $11.3 billion. The reported gross margin expanded by 10 basis points to&nbsp;52.1%, and the core gross margin was flat year-over-year.
Gains included 170 basis points from productivity savings and 30 basis points from pricing, offset by 90 basis points from higher commodity costs, 60 basis points from unfavorable mix, and 40 basis points from product reinvestments.
Operating margin expanded 30 basis points to&nbsp;26.7% while operating income for the quarter rose 1%&nbsp;to&nbsp;$5.80 billion.
Adjusted EPS of&nbsp;$1.93 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beat the analyst consensus of&nbsp;$1.90.</a>
P&amp;G held&nbsp;$12.16 billion&nbsp;in cash and equivalents as of September 30. Operating cash flow for the quarter was&nbsp;$4.3 billion.
The company returned around $4.4&nbsp;billion&nbsp;of value to shareholders via&nbsp;$2.4 billion&nbsp;in dividend payments and&nbsp;$1.9 billion&nbsp;of share repurchases.
&#8220;We remain committed to our integrated growth strategy of a focused product portfolio of daily use categories where performance drives brand choice, superiority — across product performance, packaging, brand communication, retail execution and consumer and customer value — productivity, constructive disruption and an agile and accountable organization,&#8221; said Board Chairman, President, and CEO Jon Moeller.
Outlook: P&amp;G reaffirmed FY25 guidance for all-in sales growth of&nbsp;2%&nbsp;–&nbsp;4%&nbsp;and <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">organic sales growth of&nbsp;3%&nbsp;–&nbsp;5%</a>.
This&nbsp;outlook equates to FY25 revenue of&nbsp;$85.72 billion&nbsp;–&nbsp;$87.40 billion&nbsp;(versus an estimate of&nbsp;$86.06 billion) and adjusted EPS of&nbsp;$6.91&nbsp;–<a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/40037468/why-gillette-parent-procter-gamble-shares-are-tumbling-today" rel="noreferrer noopener"> $7.05&nbsp;(vs. consensus of $6.97)</a>.
P&amp;G reaffirmed its outlook for adjusted free cash flow productivity of&nbsp;90%, payment of around&nbsp;$10 billion in dividends and repurchasing&nbsp;$6 billion to&nbsp;$7 billion of common shares in fiscal 2025.
Investors can gain exposure to the stock via&nbsp;iShares U.S. Consumer Staples ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYK#NYSE">IYK</a>) and Fidelity MSCI COnsumer Staples Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSTA#NYSE">FSTA</a>).
Price Action: PG shares are down 0.81% at $170.88 premarket at the last check Friday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41397178/procter-gamble-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earning" target="_blank" rel="noreferrer noopener">Procter &amp; Gamble Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>

Earnings

Equities

Large Cap

News

Guidance

Dividends

Buybacks

Movers

FSTA

iShares Trust Dow Jones USnsumer Goods Sector Index Fund

Procter & Gamble's Mixed Bag Q1: EPS Exceeds Estimates, Reaffirms Growth Outlook & More

Macquarie analyst Tim Nollen maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Outperform and maintains $795 price target.

Price Target

Analyst Ratings

NFLX

Macquarie Maintains Outperform on Netflix, Maintains $795 Price Target

Biotech

General

ARQT

Arcutis Gains Health Canada Approval For ZORYVE Foam 0.3% To Treat Seborrheic Dermatitis In Patients Aged 9 And Older; Marks First New Mechanism Topical Treatment For Condition In Canada In Over 20 Years

Susquehanna analyst Biju Perincheril maintains Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) with a Positive and lowers the price target from $78 to $77.

Susquehanna Maintains Positive on Occidental Petroleum, Lowers Price Target to $77

~10% Shareholder Believes Proposed Sale Represents an Egregious "Take Under" and Significantly Undervalues the Company
Urges the Board to Consider Shareholders' Best Interests and Disclose the Company's 2025 Projections so Investors Can Accurately Value the Company Against the Deal Price
Bradley L. Radoff, who collectively with his affiliates owns approximately 9.9% of the outstanding shares of GSE Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVP#NASDAQ">GVP</a>) ("GSE" or the "Company"), today sent the below letter to GSE Systems' Board of Directors (the "Board") indicating its opposition to the proposed take-private merger with Pelican Energy Partners ("Pelican").
&#x2A;&#x2A;&#x2A;
GSE Systems, Inc. 6940 Columbia Gateway Drive, Suite 470 Columbia, MD 21046 Attention: The Board of Directors
October 18, 2024
Members of the Board,
I am one of GSE's largest shareholders, with an approximately 9.9% stake in the Company. After reviewing the Company's belated and limited disclosures, I believe the proposed sale to Pelican significantly undervalues the Company and puts leadership's interests ahead of shareholders' best interests.
The Board, which collectively has limited public company experience and de minimis share ownership, appears to have allowed the Company to develop liquidity issues that have become the basis for what is seemingly a fire sale. Now, with this deal, the Board is seemingly doubling down on its missteps by giving up on the Company right as the nuclear power industry is entering a renaissance that should be a significant tailwind for GSE and its prospects for enhanced value creation.
Despite GSE's apparent runway for improved financial performance, you have refused to provide a view on the business for 2025. As a result, shareholders are unable to appropriately analyze the Company's prospects and evaluate a standalone future relative to the current deal. The Board's contention that it cannot provide projections because management's forecasts have historically been unreliable simply serves as an acknowledgment of your failures when it comes to governing the business and overseeing the executive leadership you put in place.
With respect to your decision to deprive shareholders of relevant information, it is highly unusual that the Company's definitive proxy statement for the merger did not contain forward-looking business projections. I appear to be one of the many shareholders who are disappointed with this insufficient disclosure. The Company's Form-8-K filed on October 8th, 2024 – just two weeks prior to the shareholder vote – was purportedly only put out in response to "demand letters alleging similar deficiencies and/or omissions regarding the disclosures made in the Preliminary Proxy Statement or the Definitive Proxy Statement."1
In the October 8th 8-K, GSE provided a mere glimpse of very encouraging and positive projections that implied more than $0.30 of quarterly earnings for a Company that currently trades at around $4. The projections, while incomplete, appear to show that the Company is beginning to materially benefit from the nuclear resurgence. Given this context, I am calling on you to provide the market with customary disclosures regarding the Company's forward-looking projections so shareholders can make the most informed decision on the transaction. If the Company continues to provide such limited disclosures as it did in the October 8th 8-K, then it should at least reset the record date for the Pelican merger to enable the investment community to sufficiently digest this new, albeit limited, information.
While the Company's legal counsel and bankers – who stand to make millions if the deal goes through – may have signed off on the disclosures to this point, the Board should know that this deal fails the smell test. Nothing in the merger agreement prevents you from providing more information and transparency to shareholders. I believe your decision to effectively keep GSE shareholders in the dark will define your directorship at GSE and be a black mark for any of you who intend to pursue other director opportunities. Shareholders have long memories.
While you have trumpeted Institutional Shareholder Services' recent report as an endorsement, I don't believe shareholders should give it any credence. The report neglects to mention the lack of initial projections, the magnitude of the late projections and the recent trading activity indicating that shareholders believe there is more value than is being offered by Pelican. In fact, approximately 30% of the Company's outstanding shares have traded at or above the deal price this week.
In closing, I believe an independent GSE has significant upside potential. The Board failed to provide projections prior to the record date and then reluctantly offered limited disclosure just two weeks prior to the shareholder meeting. This set of circumstances, combined with a comical fairness opinion and egregious transaction expenses, are very troubling. I once again demand normal course forward projections so that shareholders, who are the owners of the business, can fairly evaluate the Pelican transaction.
Sincerely,
Bradley L. Radoff

Management

~10% Shareholder Bradley L. Radoff Issues Open Letter To GSE Systems' Board Of Directors To State Opposition To Proposed Sale To Pelican Energy Partners; Believes Proposed Sale Represents An Egregious "Take Under" And Significantly Undervalues The Company

Susquehanna analyst Biju Perincheril maintains Hess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>) with a Neutral and raises the price target from $149 to $154.

Susquehanna Maintains Neutral on Hess, Raises Price Target to $154

Rosenblatt analyst Barton Crockett maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Neutral and raises the price target from $635 to $680.

Rosenblatt Maintains Neutral on Netflix, Raises Price Target to $680

Cantor Fitzgerald analyst Josh Schimmer reiterates Zura Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZURA#NASDAQ">ZURA</a>) with a Overweight.

Reiteration

ZURA

Cantor Fitzgerald Reiterates Overweight on Zura Bio

As of Oct. 18, 2024, two stocks in the communication services sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">T-Mobile Us Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>)</h3>
<ul>
<li>T-Mobile announced redemption of Sprint 7.625% notes due Feb. 15, 2025. The company's stock gained around 13% over the past month and has a <a href="https://www.benzinga.com/quote/TMUS">52-week high of $222.73</a>.</li>
<li>RSI Value: 82.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>TMUS Price Action: Shares of T-Mobile Us gained 1% to close at $221.95 on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>)</h3>
<ul>
<li>Sify Technologies will announce financial results for the second quarter on Tuesday, Oct. 22. The company's stock gained around 54% over the past month and <a href="https://www.benzinga.com/quote/SIFY">has a 52-week high</a> of $12.30.</li>
<li>RSI Value: 70.98</li>
<li>SIFY Price Action: Shares of Sify rose 14.8% to close at $3.73 on Thursday. </li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41379749/abbvie-is-doing-very-well-but-jim-cramers-favorite-abbott-laboratories">AbbVie Is Doing &#8216;Very Well&#8217; But Jim Cramer&#8217;s Favorite? Abbott Laboratories</a></li>
</ul>

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

SIFY

TMUS

Top 2 Tech And Telecom Stocks That May Crash In Q4

Susquehanna analyst Biju Perincheril maintains Diamondback Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) with a Positive and lowers the price target from $237 to $233.

FANG

Susquehanna Maintains Positive on Diamondback Energy, Lowers Price Target to $233

One step closer to achieving public reimbursement of AMVUTTRA&#xAE; for hATTR patients in Canada
MISSISSAUGA, ON, Oct. 18, 2024 /CNW/ - Alnylam Canada ULC is pleased to announce that it has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for the public reimbursement of AMVUTTRA&#xAE; (vutrisiran injection), an RNAi therapeutic administered by quarterly subcutaneous injection, for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis).1&nbsp;This comes following a positive recommendation from the Canadian Drug Agency (CDA) and the Institut national d'excellence en santé et services sociaux (INESSS), and signals the next step in the process where individual participating provinces and territories will start to list&nbsp;AMVUTTRA&#xAE; on their formularies.

Global

ALNY

Alnylam Canada Signs LOI From Pan-Canadian Pharmaceutical Alliance For The Public Reimbursement Of AMVUTTRA For The Treatment Of Hereditary Transthyretin-Mediated Amyloidosis In Adults

Susquehanna analyst Biju Perincheril maintains Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) with a Positive and lowers the price target from $63 to $62.

Susquehanna Maintains Positive on Devon Energy, Lowers Price Target to $62

Telsey Advisory Group analyst Dana Telsey maintains Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) with a Outperform, adjusts target to $183 from $183 (forward stock split 6:1).

DECK

Telsey Advisory Group Maintains Outperform on Deckers Outdoor, Adjusts Price Target To $183 (forward stock split 6:1)

Susquehanna analyst Biju Perincheril maintains ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) with a Positive and lowers the price target from $147 to $144.

Susquehanna Maintains Positive on ConocoPhillips, Lowers Price Target to $144

Cantor Fitzgerald analyst Andres Sheppard initiates coverage on PureCycle Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) with a Overweight rating and announces Price Target of $14.

Initiation

Cantor Fitzgerald Initiates Coverage On PureCycle Technologies with Overweight Rating, Announces Price Target of $14

<a href="https://www.aljazeera.com/news/liveblog/2024/10/18/live-israel-says-hamas-chief-yahya-sinwar-killed-war-on-gaza-to-continue" title="https://www.aljazeera.com/news/liveblog/2024/10/18/live-israel-says-hamas-chief-yahya-sinwar-killed-war-on-gaza-to-continue">https://www.aljazeera.com/news/liveblog/2024/10/18/live-israel-says-hamas-chief-yahya-sinwar-killed-war-on-gaza-to-continue</a>

Macro Economic Events

Economics

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

Hamas Senior Official Al-Hayya Says Group Is Continuing Path Until Achieving Palestinian People's Ambitions; Says Sinwar's Death Will Turn Into A Curse On 'The Occupiers'; Sinwar's Death Will Only Strengthen The Group; Israeli Hostages Will Not Return Until Aggression On Gaza Stops And Withdrawal Of Israeli Forces

Susquehanna analyst Biju Perincheril maintains APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) with a Positive and lowers the price target from $52 to $48.

Susquehanna Maintains Positive on APA, Lowers Price Target to $48

WIIM

DRUG

Bright Minds Biosciences shares are trading higher. The company announced a $35 million non-brokered private placement.

<h3>Gainers</h3>
<ul>
<li>Lion Group Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGHL#NASDAQ">LGHL</a>) shares rose 29.8% to $0.27 during Friday's pre-market session. The company's market cap stands at $1.8 million. </li>
<li>Prestige Wealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PWM#NASDAQ">PWM</a>) stock moved upwards by 12.49% to $0.9. The market value of their outstanding shares is at $10.8 million. </li>
<li>UP Fintech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NASDAQ">TIGR</a>) stock moved upwards by 9.74% to $7.88. The market value of their outstanding shares is at $1.2 billion. </li>
<li>Yiren Digital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YRD#NYSE">YRD</a>) stock increased by 9.54% to $6.08. The company's market cap stands at $528.5 million. </li>
<li>Garden Stage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSIW#NASDAQ">GSIW</a>) stock rose 7.23% to $1.63. The market value of their outstanding shares is at $25.4 million. </li>
<li>LexinFintech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) shares rose 7.01% to $3.05. The market value of their outstanding shares is at $501.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Pineapple Financial (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PAPL#AMEX">PAPL</a>) shares declined by 8.3% to $0.66 during Friday's pre-market session. The company's market cap stands at $4.8 million. </li>
<li>Netcapital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCPL#NASDAQ">NCPL</a>) shares declined by 5.15% to $1.66. The company's market cap stands at $1.2 million. </li>
<li>Santech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STEC#NASDAQ">STEC</a>) stock declined by 4.89% to $1.51. The company's market cap stands at $42.3 million. </li>
<li>Western Alliance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>) stock declined by 4.18% to $90.0. The company's market cap stands at $9.9 billion. The company's, Q3 earnings came out yesterday. </li>
<li>New York Community (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYCB#NYSE">NYCB</a>) stock decreased by 4.12% to $11.87. The market value of their outstanding shares is at $4.9 billion. </li>
<li>MicroSectors FANG Index -3X Inverse Leveraged ETNs due January 8, 2038 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNGD#NYSE">FNGD</a>) stock decreased by 3.62% to $19.47. 
See Also: <a href="http://www.benzinga.com/money/best-financial-services-stocks/" title="www.benzinga.com/money/best-financial-services-stocks/">www.benzinga.com/money/best-financial-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FNGD

GSIW

LGHL

NCPL

NYCB

PAPL

STEC

TIGR

12 Financials Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock increased by 151.9% to $1.11 during Friday's pre-market session. The company's market cap stands at $3.1 million. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) stock rose 71.13% to $1.66. The company's market cap stands at $4.7 million. </li>
<li>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) shares increased by 39.06% to $4.77. The company's market cap stands at $2.6 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock moved upwards by 21.83% to $0.52. The company's market cap stands at $1.9 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock increased by 21.01% to $1.67. The market value of their outstanding shares is at $284.9 million. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares increased by 10.77% to $0.53. The market value of their outstanding shares is at $11.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Orgenesis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGS#NASDAQ">ORGS</a>) shares declined by 37.9% to $2.01 during Friday's pre-market session. The market value of their outstanding shares is at $9.5 million. </li>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) shares decreased by 30.11% to $0.65. The company's market cap stands at $4.2 million. </li>
<li>NKGen Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) shares declined by 29.02% to $0.5. The company's market cap stands at $17.5 million. </li>
<li>Chromocell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) shares fell 12.81% to $0.67. The company's market cap stands at $3.8 million. </li>
<li>Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) shares decreased by 12.68% to $0.46. The market value of their outstanding shares is at $13.7 million. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) shares declined by 11.91% to $0.66. The market value of their outstanding shares is at $3.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKAN

CHRO

CTCX

HEPA

KZIA

MTEM

NKGN

ORGS

TNON

TVGN

VTAK

YCBD

12 Health Care Stocks Moving In Friday's Pre-Market Session

Warning: OUT is at high risk of performing badly

Analysts have been eager to weigh in on the Real Estate sector with new ratings on Postal Realty (PSTL – Research Report) and Outfront Media (OUT –...

Analysts' Opinions Are Mixed on These Real Estate Stocks: Postal Realty (PSTL) and Outfront Media (OUT)

The Return Of Volatility

I still want to address recessionary environments now – even while the markets are back on their "everything is awesome" kick. Today, we'll look at sectors to avoid.

Avoid These Stocks If A Recession Hits

James Goss, an analyst from Barrington, reiterated the Buy rating on Outfront Media (OUT – Research Report). The associated price target was raised...

Outfront Media Buy Rating: Steady Growth and Digital Transition Signal Strong Revenue Potential

Outfront Media: An Attractive 7% Dividend Yielder With Double-Digit Upside Potential

Outfront Media: After Surging, A Downgrade Is In Order

EPR Properties: Poised To Benefit From Lower Interest Rates And Changing Consumer Habits

Cove Street Capital Q3 2024 Letter To Shareholders

U.S. REITs Log Dip In Short Interest In September

AGNC

AGNCL

AGNCM

AGNCN

AGNCO

AGNCP

APLE

BBRE

BLDG

BXMT

CHMI

CIMN

CLDT

CLMB

CMTG

CUBE

EQIX

FCPT

FREL

GMRE

GPMT

GQRE

HAUS

HAUZ

HOMZ

IFGL

INDS

INVH

IRET

KBWY

LAMR

MFAN

MFAO

MORT

NAIL

NETL

NTST

NURE

PFFR

PLDGP

PPTY

PSTL

RDOG

RDVT

REET

REGCO

REGCP

REIT

RIET

ROOF

SBAC

SBRA

SCHH

SEVN

SRVR

STWD

USRT

VICI

VIOO

VNORP

VRAI

VSAT

WELL

WHLR

XLRE

Entertainment

Press Releases

OUTFRONT Media and Bell Media Announce Closing of the Sale of OUTFRONT Media's Canadian Business

OUTFRONT Media To Report 2024 Second Quarter Results on August 6, 2024

OUTFRONT Media Announces Quarterly Dividend

OUTFRONT Media Reports Second Quarter 2024 Results

OUTFRONT Media Chief Financial Officer Matthew Siegel to Participate in the Oppenheimer 27th Annual Technology, Internet & Communications Conference

OUTFRONT Media Chief Executive Officer Jeremy Male to Participate in Citi's 2024 Global TMT Conference

Women's Wear Daily Celebrates National Hispanic Heritage Month with High Impact Campaign in Partnership with OUTFRONT

Scott Felenstein Joins OUTFRONT Media as Senior Vice President of Brand Partnerships

Social Media

Million Mammogram Challenge Launches with OUTFRONT Media in New York City in Partnership with MaleRoom Founder Mindie Kaplan and Imerman Angels

Comments

Outfront Media

Notizie

Ultime notizie per Outfront Media (NYSE:OUT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO